GlassScriptPhysician profile
David Charles King
NPI 1154859452
$6,126.68
in general payments reported to CMS, 2019-2025
22 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $761 · 2023: $2,220 · 2024: $1,477 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Travel and Lodging: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.14 |
| Travel and Lodging | $1,414.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,749.85 | 2021-2025 | Eterna, Proclaim |
| Relievant Medsystems, INC. | $1,360.20 | 2023 | Intracept |
| Boston Scientific Corporation | $1,206.81 | 2024-2025 | Intracept, General - Pain Management, General - Therapies |
| Abbvie INC. | $766.75 | 2021-2025 | |
| Forte Bio-Pharma LLC | $166.78 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Teva Pharmaceuticals USA, INC. | $148.63 | 2021-2025 | Ajovy |
| Collegium Pharmaceutical, INC. | $144.34 | 2021-2025 | Xtampza, Belbuca |
| Lundbeck LLC | $118.66 | 2022-2025 | Vyepti |
| Averitas Pharma INC. | $91.97 | 2023-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $60.36 | 2025 | |
| Lilly USA, LLC | $51.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $49.16 | 2021 | |
| Azurity Pharmaceuticals, INC. | $38.58 | 2024 | Horizant |
| Pfizer INC. | $25.68 | 2021 | |
| Si-Bone, INC. | $25.16 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $24.80 | 2024 | Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $20.92 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $18.90 | 2023 | Iovera, Zilretta, Exparel |
| Novartis Pharmaceuticals Corporation | $17.73 | 2021 | |
| Medtronic, INC. | $14.90 | 2024 | Synchromedii |
| Idorsia Pharmaceuticals US INC | $13.23 | 2023 | Quviviq |
| Amgen INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.